03.12.26 -- Outsourcing? When Both Sides Of The Table Are Investor-Backed, Everything Changes

Take action to improve diversity in clinical trials by addressing underrepresentation and ensuring equitable access to medical interventions, as emphasized by the FDA’s new 2025 guidance.

Learn how to synthesize individual symptomatic data into a comprehensive narrative of tolerability, ultimately enhancing the clinical value and regulatory positioning of your oncology assets.

Some CNS drugs need to be assessed for their impact on driving ability. Driving simulation studies offer faster startup, lower cost, and no safety risk. Learn more and discover a real-life case study.

Complexity is no longer the exception in high stakes clinical trials, it has become the rule.

Discover why Serbia is becoming a top strategic choice for sponsors, including details of the country's strengths in key therapeutic areas, streamlined processes, and operational advantages.

Three factors often decide success or failure in FIH studies: integrating biomarkers and pharmacodynamic endpoints, including patients, and leveraging purpose-built infrastructure.

Choosing the right vendor at trial launch impacts costs, timelines, data integrity, and patient experience — yet vendor selection in clinical research remains fundamentally broken today.

Accelerate your biotech trials in Australia—cut costs by up to 60%, enroll patients in as little as 4–6 weeks, and generate FDA- and EMA-accepted data with no IND required.

Recovering lost clinical trials is an art. Learn how we triage your study’s problem areas, build recovery strategies to address your drifting trial’s performance, and deliver results.